670280-13-4 Usage
General Description
3-(aminomethyl)benzenesulfonamide hydrochloride is a chemical compound that consists of a sulfonamide functional group attached to a benzene ring, with an amino-methyl substituent. It is commonly used as a pharmaceutical ingredient, particularly as an antibiotic, diuretic, and antihypertensive agent. The hydrochloride salt form of this compound is water-soluble and can be easily administered orally or intravenously. It functions by inhibiting the synthesis of dihydrofolic acid, which is necessary for the production of purines and pyrimidines, thus disrupting the growth of bacteria and leading to their eventual death. 3-(aminomethyl)benzenesulfonamide hydrochloride has shown promising results in the treatment of various bacterial infections and is a widely used and well-tolerated medication.
Check Digit Verification of cas no
The CAS Registry Mumber 670280-13-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,0,2,8 and 0 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 670280-13:
(8*6)+(7*7)+(6*0)+(5*2)+(4*8)+(3*0)+(2*1)+(1*3)=144
144 % 10 = 4
So 670280-13-4 is a valid CAS Registry Number.
670280-13-4Relevant articles and documents
PRO-DRUG FORMING COMPOUNDS
-
Page/Page column 31, (2015/02/02)
Various prodrug compounds having the general structure: Active agent- (acid)-(linker) - SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
Multicyclic bis-amide MMP inhibitors
-
Page/Page column 86-87, (2008/06/13)
The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.
